Golden State Wealth Management LLC Takes $73,000 Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Golden State Wealth Management LLC bought a new position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund bought 695 shares of the medical equipment provider’s stock, valued at approximately $73,000.

Several other large investors also recently bought and sold shares of the stock. BLB&B Advisors LLC raised its position in shares of Zimmer Biomet by 2.1% during the 3rd quarter. BLB&B Advisors LLC now owns 4,900 shares of the medical equipment provider’s stock worth $529,000 after acquiring an additional 100 shares in the last quarter. CKW Financial Group lifted its position in shares of Zimmer Biomet by 11.7% during the 4th quarter. CKW Financial Group now owns 955 shares of the medical equipment provider’s stock worth $101,000 after buying an additional 100 shares during the last quarter. FWG Holdings LLC boosted its holdings in shares of Zimmer Biomet by 2.9% in the 3rd quarter. FWG Holdings LLC now owns 3,591 shares of the medical equipment provider’s stock valued at $372,000 after buying an additional 101 shares in the last quarter. Romano Brothers AND Company grew its position in shares of Zimmer Biomet by 1.1% in the 4th quarter. Romano Brothers AND Company now owns 9,466 shares of the medical equipment provider’s stock valued at $1,000,000 after buying an additional 102 shares during the last quarter. Finally, Financial Advocates Investment Management lifted its position in Zimmer Biomet by 3.5% in the third quarter. Financial Advocates Investment Management now owns 3,053 shares of the medical equipment provider’s stock valued at $330,000 after acquiring an additional 103 shares during the last quarter. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Stock Performance

Shares of ZBH stock opened at $100.40 on Tuesday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.70 and a current ratio of 1.91. The stock has a market cap of $19.99 billion, a PE ratio of 22.56, a P/E/G ratio of 1.83 and a beta of 1.02. Zimmer Biomet Holdings, Inc. has a 1 year low of $99.67 and a 1 year high of $133.90. The stock has a fifty day moving average price of $107.34 and a 200 day moving average price of $108.07.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same period last year, the firm posted $2.20 EPS. Sell-side analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.25 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Monday, December 30th were paid a dividend of $0.24 per share. The ex-dividend date was Monday, December 30th. This represents a $0.96 annualized dividend and a dividend yield of 0.96%. Zimmer Biomet’s dividend payout ratio is currently 21.57%.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on the company. JPMorgan Chase & Co. upgraded Zimmer Biomet from a “neutral” rating to an “overweight” rating and lifted their target price for the stock from $125.00 to $128.00 in a research report on Tuesday, December 17th. JMP Securities reiterated a “market outperform” rating and issued a $140.00 price objective on shares of Zimmer Biomet in a research note on Friday. Truist Financial reissued a “hold” rating and issued a $113.00 price objective (down from $118.00) on shares of Zimmer Biomet in a report on Monday. Raymond James reduced their price target on shares of Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating for the company in a research report on Friday. Finally, Barclays lowered their price objective on shares of Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating on the stock in a research report on Monday. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and ten have given a buy rating to the company’s stock. According to data from MarketBeat.com, Zimmer Biomet currently has an average rating of “Hold” and an average price target of $124.15.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.